Sagimet Biosciences (NASDAQ:SGMT) Announces Earnings Results, Misses Expectations By $0.01 EPS

Posted by Geri Gentry on Aug 12th, 2026

Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01), FiscalAI reports.

Here are the key takeaways from Sagimet Biosciences’ conference call:

Sagimet plans to initiate a Phase III denifanstat trial for moderate-to-severe acne within the next few months, enrolling approximately 800 patients, including 450 adolescents aged 12–17. Top-line results are expected shortly after last patient, last dose, anticipated around this time next year.
The company highlighted Ascletis’ 480-patient Phase III trial in China, which reportedly delivered statistically significant improvements in investigator-assessed clear/almost-clear skin and inflammatory and non-inflammatory lesion counts, with about a 20-percentage-point placebo-adjusted improvement in the primary skin-clearance measure and no serious or Grade 3 adverse events.
Management sees a substantial commercial opportunity in the estimated 10–15 million U.S. patients with moderate-to-severe acne, particularly those inadequately served by oral antibiotics and topicals. Early payer research suggested potential pricing above existing acne therapies, with management citing a preliminary floor of roughly $1,200–$1,500 per month, although no price has been set.
Sagimet is developing additional FASN inhibitors, including a more potent oral candidate expected to enter Phase II by year-end and a topical formulation planned for first-in-human studies in early 2028. The company also acknowledged that denifanstat’s effects depend on continued treatment, with sebum and acne symptoms returning within roughly four to six weeks after discontinuation.

Sagimet Biosciences Stock Performance

Shares of NASDAQ SGMT traded up $0.18 during midday trading on Wednesday, reaching $9.70. The stock had a trading volume of 139,972 shares, compared to its average volume of 1,162,402. The firm has a market cap of $315.94 million, a price-to-earnings ratio of -7.26 and a beta of 3.37. Sagimet Biosciences has a twelve month low of $4.50 and a twelve month high of $10.06. The company’s 50 day moving average price is $7.34 and its 200 day moving average price is $6.50.

Analysts Set New Price Targets

Several equities analysts have issued reports on SGMT shares. Oppenheimer restated an “outperform” rating on shares of Sagimet Biosciences in a research report on Friday, May 1st. Guggenheim reduced their price objective on shares of Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Sagimet Biosciences in a report on Friday, July 17th. Citizens Jmp lowered their target price on Sagimet Biosciences from $35.00 to $12.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 19th. Finally, Canaccord Genuity Group lifted their target price on Sagimet Biosciences from $28.00 to $49.00 and gave the stock a “buy” rating in a report on Monday, May 4th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $25.17.

Get Our Latest Stock Analysis on Sagimet Biosciences

Insider Transactions at Sagimet Biosciences

In other news, insider Elizabeth Rozek sold 10,545 shares of the stock in a transaction on Monday, July 20th. The shares were sold at an average price of $7.76, for a total transaction of $81,829.20. Following the completion of the sale, the insider directly owned 224,414 shares in the company, valued at $1,741,452.64. This represents a 4.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David Happel sold 64,051 shares of the business’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $7.76, for a total transaction of $497,035.76. Following the completion of the transaction, the chief executive officer owned 741,570 shares in the company, valued at approximately $5,754,583.20. The trade was a 7.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 93,440 shares of company stock worth $719,441 over the last three months. 11.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Royal Bank of Canada boosted its position in shares of Sagimet Biosciences by 819.2% during the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock valued at $29,000 after purchasing an additional 4,391 shares in the last quarter. Bank of America Corp DE increased its holdings in Sagimet Biosciences by 81.8% in the second quarter. Bank of America Corp DE now owns 9,943 shares of the company’s stock worth $76,000 after purchasing an additional 4,473 shares in the last quarter. Virtu Financial LLC bought a new stake in Sagimet Biosciences in the fourth quarter worth approximately $62,000. Jefferies Financial Group Inc. acquired a new position in Sagimet Biosciences in the third quarter valued at approximately $95,000. Finally, LPL Financial LLC lifted its stake in Sagimet Biosciences by 31.3% in the fourth quarter. LPL Financial LLC now owns 20,574 shares of the company’s stock valued at $122,000 after buying an additional 4,899 shares during the period. 87.86% of the stock is owned by institutional investors and hedge funds.

Sagimet Biosciences Company Profile

(Get Free Report)

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.